AKT1 and ovarian carcinoma: Thus, β-elemene may enhance cisplatin sensitivity in resistant ovarian cancer cells by abrogating cisplatin-induced PI3K activity and the PI3K/Akt signaling pathway, resulting in decreased IAP expression and increased apoptotic cell death.